|
|
You are searching for "CFAMM00376647" in compound. Total 1 results found.
Click on CFAM IDs and names to search or view in CFAM, click on external IDs to view the entity in its source database.
CFAM Mol ID | CFAMM00376647 |
Family | CFFBM7035 RAC-alpha serine/threonine-protein kinase inhibitor 2-[(3,4-difluorophenyl)methyl]-1-[4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one family |
Superfamily | CFSBM4004 Mitogen-activated protein kinase 9 and Mitogen-activated protein kinase 8 Binder Superfamily |
Class | CFCBM1469 Class 4519 |
External ID | CHEMBL1632382 |
External Source | CHEMBL |
PubChem CID |
53319315 |
Functional Category |
Bioactive |
Molecule Name |
1-[4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-2-[(4-methylphenyl)methyl]-3-(propan-2-ylamino)propan-1-one |
IUPAC Name |
1-[4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-2-[(4-methylphenyl)methyl]-3-(propan-2-ylamino)propan-1-one |
Synonyms |
CHEBI:1155473 |
InChi |
InChI=1S/C25H35N5OS/c1-17(2)26-14-21(13-20-7-5-18(3)6-8-20)25(31)30-11-9-29(10-12-30)24-23-19(4)32-15-22(23)27-16-28-24/h5-8,16-17,19,21,26H,9-15H2,1-4H3/t19-,21?/m0/s1 |
InChiKey |
FPCQIAFSAOSSKP-ZQRQZVKFSA-N |
Formula | C25H35N5OS |
Molecular Weight | 453.64 |
Cross Link | CHEMBL1632382 |
Structure |
|
Statistics of CFAM Database |
CFAM currently contains 490,279 molecules in 87,136 families, 34,880 superfamilies and 11,643 classes. |
How to cite our database |
C. Zhang, L. Tao, C. Qin, P. Zhang, S.Y. Chen, X. Zeng, F. Xu, Z. Chen, S.Y. Yang and Y.Z. CFam: A Chemical Families Database Based on Iterative Selection of Functional Seeds and Seed-Directed Compound Clustering.
Nucl. Acids Res. 43 (D1): D558-D565 (2015) (First published online: November 20, 2014).
|
Last update by |
2014.08.29
|
48680 visits since 2014 .........
Dr.
Chen Yuzong
Deputy
Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|